Topics

Tissue Microarray of Hematological Malignancies

2019-11-03 15:11:09 | BioPortfolio

Summary

The aim of the study is to create new tools for improving management of patients with hematological malignancies by combining extensive clinical data from patients newly diagnosed with hematological malignancies and innovative laboratory analyses made on available tissue samples in regional biobanks from these patients.

Description

Firstly, clinical information is collected on all hematological malignancies diagnosed in our hospital district area retrospectively between the years 2000 and 2019. Clinical outcomes, laboratory results, clinically relevant diagnoses, characteristics defining clinical stage and established prognostic parameters are gathered.

Simultaneously a tissue microarray (TMA) of diagnostic samples is compiled using representative annotated tissue areas. This TMA is used in combination with additional control material to identify prognostic and predictive biomarkers.

A combined microarray dataset of hematological malignancies (Hemap) is utilized to point out genes of possible drug targets, disease specific markers, prognostic markers, or predictive markers.

The clinical datasets and Hemap dataset is ultimately utilized to gain knowledge, new tools for prognostication and diagnostics, and targets for treatment.

Study Design

Conditions

Hematological Malignancies

Status

Not yet recruiting

Source

Tampere University Hospital

Results (where available)

View Results

Links

Published on BioPortfolio: 2019-11-03T15:11:09-0500

Clinical Trials [651 Associated Clinical Trials listed on BioPortfolio]

A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies

The main objectives of this study are to evaluate the side effects of MKC-1 and to determine a safe dose of MKC-1 for future studies in patients with hematological malignancies

Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells

The investigators have previously shown the absence of toxicity of Treg-depleted-DLI and the possibility to triggering alloreactivity (GVHD/GVT) in relapsing patients dealing with hematolo...

MS Detection of Somatic Mutations in Hematological Malignancies

Detection of somatic mutations in hematological malignancies is now routinely assessed by NGS sequencing. This powerful approach is nevertheless time consuming and its costs represent limi...

Evolution of Thromboelastography During Tranexamic Acid Treatment

Patients with hematological malignancies are at increased risk of bleeding, especially during intensive chemotherapy. The aim of this study is to compare by thromboelastography changes dur...

Intrabone Infusion of Cord Blood in Adults With Hematological Malignancies

The purpose of this study is to evaluate the engraftment of donor hemopoiesis (proportion of transplanted patients with successful engraftment at day +42) in adult patients affected by hig...

PubMed Articles [1168 Associated PubMed Articles listed on BioPortfolio]

Saprochaete clavata Infections in Patients Undergoing Treatment for Hematological Malignancies: A Report of a Monocentric Outbreak and Review of the Literature.

Saprochaete clavata is a a rare cause of fungemia with deep organ involvement in patients with hematological malignancies with reported mortality rates of 60-80%.

Heterozygous loss of Srp72 in mice is not associated with major hematological phenotypes.

Familial cases of hematological malignancies are associated with germline mutations. In particular, heterozygous mutations of SRP72 correlate with the development of myelodysplasia and bone marrow apl...

CAR T-cell Therapy in Hematologic Malignancies: A Voyage in Progress.

The development of chimeric antigen receptor (CAR) T-cell therapy for select hematological malignancies represents one of the most remarkable therapeutic advances in the past decade. Currently, CD19-t...

Hepatitis B and C virus infection and risk of hematological malignancies.

Hepatitis B virus (HBV) and hepatitis C virus (HCV) are classified as oncogenic human viruses. Chronic HBV and HCV infections are associated with higher risk of hematological malignancy development. D...

Antibiotic treatment ameliorates Ten-eleven Translocation 2 (TET2) loss-of-function associated hematological malignancies.

TET2 is among the most frequently mutated genes in hematological malignancies, as well as in healthy individuals with clonal hematopoiesis. Inflammatory stress is known to promote the expansion of Tet...

Medical and Biotech [MESH] Definitions

Use of HIRUDINS as an anticoagulant in the treatment of cardiological and hematological disorders.

A hematopoietic growth factor which promotes proliferation and maturation of neutrophil granulocytes. Clinically it is effective in decreasing the incidence of febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive therapy or in reducing the duration of neutropenia and neutropenia-related clinical sequelae in patients with non-myeloid malignancies undergoing myeloblastive chemotherapy followed by BMT. It has also been used in AIDS patients with CMV retinitis being treated with GANCICLOVIR. (Gelman CR, Rumack BH & Hess AJ (eds): DRUGDEX(R) System. MICROMEDEX, Inc., Englewood, Colorado (Edition expires 11/30/95))

A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.

An alkylating agent of value against both hematologic malignancies and solid tumors.

A condition caused by a brief whole body exposure to more than one sievert dose equivalent of radiation. Acute radiation syndrome is initially characterized by ANOREXIA; NAUSEA; VOMITING; but can progress to hematological, gastrointestinal, neurological, pulmonary, and other major organ dysfunction.

More From BioPortfolio on "Tissue Microarray of Hematological Malignancies"

Quick Search

Relevant Topics

DNA Microarray
A DNA microarray or biochip is a collection of microscopic DNA spots attached to a solid surface used to measure the expression levels of large numbers of genes simultaneously or to genotype multiple regions of a genome.

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Searches Linking to this Trial